Karyopharm Therapeutics Inc. (KPTI): Price and Financial Metrics

Karyopharm Therapeutics Inc. (KPTI): $1.36

0.16 (+13.48%)

POWR Rating

Component Grades








Add KPTI to Watchlist
Sign Up

KPTI Price/Volume Stats

Current price $1.36 52-week high $6.01
Prev. close $1.20 52-week low $1.11
Day low $1.23 Volume 5,510,001
Day high $1.41 Avg. volume 2,632,971
50-day MA $1.48 Dividend yield N/A
200-day MA $2.62 Market Cap 155.73M

KPTI Stock Price Chart Interactive Chart >


  • Growth is the dimension where KPTI ranks best; there it ranks ahead of 85.98% of US stocks.
  • The strongest trend for KPTI is in Growth, which has been heading up over the past 177 days.
  • KPTI ranks lowest in Momentum; there it ranks in the 3rd percentile.

KPTI Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for KPTI is -2.05 -- better than only 4.54% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -4.44 for KARYOPHARM THERAPEUTICS INC; that's greater than it is for only 3.64% of US stocks.
  • KARYOPHARM THERAPEUTICS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -123.57%, greater than the shareholder yield of just 4.71% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to KARYOPHARM THERAPEUTICS INC, a group of peers worth examining would be FCEL, TVTX, WATT, MIMO, and CASA.
  • KPTI's SEC filings can be seen here. And to visit KARYOPHARM THERAPEUTICS INC's official web site, go to www.karyopharm.com.

KPTI Valuation Summary

  • KPTI's price/sales ratio is 0.9; this is 52.63% lower than that of the median Healthcare stock.
  • KPTI's price/sales ratio has moved down 1022 over the prior 120 months.

Below are key valuation metrics over time for KPTI.

Stock Date P/S P/B P/E EV/EBIT
KPTI 2023-09-22 0.9 -1.8 -0.9 -1.9
KPTI 2023-09-21 1.0 -2.0 -1.0 -2.0
KPTI 2023-09-20 0.9 -1.9 -1.0 -2.0
KPTI 2023-09-19 0.9 -1.9 -1.0 -2.0
KPTI 2023-09-18 0.9 -1.8 -0.9 -1.9
KPTI 2023-09-15 0.9 -1.9 -1.0 -2.0

KPTI Growth Metrics

    The 4 year net cashflow from operations growth rate now stands at -96.91%.
  • The 3 year revenue growth rate now stands at 1043.08%.
  • Its 4 year cash and equivalents growth rate is now at 682.73%.
KPTI's revenue has moved up $98,198,000 over the prior 34 months.

The table below shows KPTI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 157.074 -149.554 -165.291
2022-09-30 249.763 -97.236 -88.065
2022-06-30 251.307 -92.821 -103.553
2022-03-31 234.229 -113.425 -108.073
2021-12-31 209.819 -107.116 -124.088
2021-09-30 118.65 -163.225 -206.229

KPTI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • KPTI has a Quality Grade of C, ranking ahead of 58.11% of graded US stocks.
  • KPTI's asset turnover comes in at 0.338 -- ranking 138th of 681 Pharmaceutical Products stocks.
  • CAPR, DRNA, and PLXP are the stocks whose asset turnover ratios are most correlated with KPTI.

The table below shows KPTI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.338 0.965 -0.614
2021-03-31 0.347 0.975 -0.545
2020-12-31 0.299 0.975 -0.534
2020-09-30 0.255 0.967 -0.576
2020-06-30 0.239 0.956 -0.607
2020-03-31 0.189 0.945 -0.671

KPTI Price Target

For more insight on analysts targets of KPTI, see our KPTI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.22 Average Broker Recommendation 1.6 (Moderate Buy)

Karyopharm Therapeutics Inc. (KPTI) Company Bio

Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company was founded in 2008 and is based in in Newton, Massachusetts.

KPTI Latest News Stream

Event/Time News Detail
Loading, please wait...

KPTI Latest Social Stream

Loading social stream, please wait...

View Full KPTI Social Stream

Latest KPTI News From Around the Web

Below are the latest news stories about KARYOPHARM THERAPEUTICS INC that investors may wish to consider to help them evaluate KPTI as an investment opportunity.

Karyopharm to Participate at Upcoming Investor Conferences

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September:

Yahoo | September 5, 2023

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 58,850 restricted stock units (RSUs) to six newly-hired employees. These RSU awards were granted as of August 31, 2023 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Na

Yahoo | September 1, 2023

Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Zhen Su, MD, MBA, to its Board of Directors, effective August 31, 2023. Dr. Su is currently Chief Executive Officer and a member of the Board of Directors at Marengo Therapeutics, Inc., a company pioneering novel T-cell targeting therapeutics to fight cancer.

Yahoo | September 1, 2023

11 Best Biotech Penny Stocks to Buy Now

In this article, we will take a look at the 11 best biotech penny stocks to buy now. To see more such companies, go directly to 5 Best Biotech Penny Stocks to Buy Now. As investors begin to see light at the end of the tunnel, their risk appetite, which had vanished amid recession risks […]

Yahoo | August 17, 2023

Dozens more biotech jobs axed as two firms make cuts

Around 60 more Boston-area biotech employees will soon lose their jobs as two companies disclose planned cuts.

Yahoo | August 3, 2023

Read More 'KPTI' Stories Here

KPTI Price Returns

1-mo -5.56%
3-mo -28.80%
6-mo -61.36%
1-year -67.92%
3-year -90.84%
5-year -92.05%
YTD -60.00%
2022 -47.12%
2021 -58.46%
2020 -19.25%
2019 104.59%
2018 -2.40%

Continue Researching KPTI

Want to see what other sources are saying about Karyopharm Therapeutics Inc's financials and stock price? Try the links below:

Karyopharm Therapeutics Inc (KPTI) Stock Price | Nasdaq
Karyopharm Therapeutics Inc (KPTI) Stock Quote, History and News - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!